Cue Biopharma Q2 revenue more than doubles, net loss widens on one-time charges

Cue Biopharma

14/08/2026 21:16

Overview
US biopharma's Q2 revenue more than doubled yr/yr, driven by milestone collaboration payments
Net loss widened sharply on one-time non-cash charges and acquisition-related payments
Company completed $50 mln private placement after quarter-end to fund clinical development

Outlook
Cue Biopharma expects CUE-221 Phase 2 data by end of Q3 2026
Company plans to initiate CUE-401 Phase 1 study by year-end 2026

Result Drivers
COLLABORATION MILESTONE - Revenue increase driven by milestone payment from Boehringer Ingelheim collaboration and license agreement
ONE-TIME LICENSE COSTS - Higher operating expenses and net loss primarily due to one-time cash payments and non-cash charges related to CUE-221 license agreement and program initiation
MANAGEMENT INTEGRATION COSTS - General and administrative expenses rose due to one-time costs from integrating new management team and related stock-based compensation

Company press release: ID:nGNXc7NhKj

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
 
$7.88 mln
 
Q2 Net Loss
 
$153.07 mln
 
Q2 Income From Operations
 
-$87.70 mln
 
Q2 Loss Per Basic Share
 
$24.14
 
Q2 Operating Expenses
 
$95.57 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Cue Biopharma, Inc. is $115.00, about 270% above its August 13 closing price of $31.08

Reuters Recommended Reads
Aug 14 - Quince Therapeutics Q2 net loss widens on acquisition charges
Aug 13 - Rani Therapeutics Q2 net loss narrows as revenue rises helped by Chugai agreement
Aug 12 - Formycon H1 revenue rises sharply on milestone payments, EBITDA loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)